An Animated Whiteboard View: Addressing the Pathophysiologic Underpinnings of cSCC: Reactivating the Immune Response

View Activity

FACULTY

Gregory A. Daniels, MD, PhD
Medical Oncologist
Professor of Medicine
University of California, San Diego
San Diego, CA

PROGRAM OVERVIEW

This online activity is focused on the management of patients with advanced or metastatic cutaneous squamous cell carcinoma.

TARGET AUDIENCE

This activity is designed to meet the educational needs of medical oncologists and other healthcare practitioners who care for patients with advanced or metastatic cutaneous squamous cell carcinoma.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Describe the role that immune dysfunction plays in the pathogenesis of cSCC
  • Discuss the factors for local recurrence or metastatic cutaneous squamous cell carcinoma to stratify the patient’s risk for systemic disease
  • Evaluate the current clinical practice guidelines for cSCC and their application to the patient care setting
  • Review the clinical trial data for immunotherapy in the treatment of advanced or metastatic cutaneous squamous cell carcinoma

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 0.75 AMA Category 1 credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour(s) of continuing nursing education of RNs and APNs.

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education for RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Gregory A. Daniels, MD, PhD, has served as a consultant and on speaker’s bureaus for Regeneron and Sanofi.

CME Content Review
The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certification as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: September 26, 2019

EXPIRATION DATE: September 26, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.